Zelira Therapeutics (AU:ZLD) has released an update.
Zelira Therapeutics has announced a major stride in its HOPE® autism drug program after receiving positive feedback from the FDA, which provides strategic clarity for upcoming clinical trials. This milestone allows Zelira to confidently prepare for their Investigational New Drug (IND) submission, specifically targeting irritability associated with Autism Spectrum Disorder in Phelan-McDermid Syndrome patients. The advancement reflects significant progress in the development of clinically validated cannabinoid-based medicines for treating autism-related symptoms.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
